Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreYour world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreFor government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MOREThis study explores the impact of The Inflation Reduction Act (IRA) of 2022 on 340B Modifiers. In August 2022, the IRA introduced provisions requiring the identification of 340B transactions. 340B modifiers — a system of codes used on some pharmacy and medical claims to identify 340B drugs — have been required by the Centers for Medicare & Medicaid Services (CMS) for Medicare Part B reimbursement, and more recently, to identify 340B drugs. Download this white paper for a deeper look into 340B Modifiers data and the impact it will have on the industry.
For a summary of this study and paper please see our fact sheet here
Gain high value access and increase the profitability of your brands
Rely on market-leading strategists to help you achieve maximum access and profitability